Research programme: anti-infectives - Stablecoin Development Corporation
Alternative Names: Aganocide®; NVC-612; NVC-638; NVC-704; NVC-727Latest Information Update: 07 Apr 2026
At a glance
- Originator NovaBay Pharmaceuticals
- Developer Stablecoin Development Corporation
- Class Alkanesulfonic acids; Chloramines; Small molecules
- Mechanism of Action
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Mycoses; Onychomycosis
Most Recent Events
- 23 Mar 2026 NovaBay Pharmaceuticals is now called Stablecoin Development Corporation
- 28 Jun 2021 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Topical)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Mycoses in USA (Topical)